CEFOXITIN FOR INJECTION 1 G — DIN 02128187
CEFOXITIN (CEFOXITIN SODIUM) : 1 G · TEVA CANADA LIMITED · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is CEFOXITIN FOR INJECTION?
CEFOXITIN FOR INJECTION 1 G contains CEFOXITIN (CEFOXITIN SODIUM) : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02128187, held by TEVA CANADA LIMITED, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 22-Nov-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CEFOXITIN FOR INJECTION used for?
Treatment of intra-abdominal, gynecological, septicemia, urinary tract, lower respiratory, bone/joint, and soft tissue infections. Perioperative prophylaxis in abdominal and vaginal surgery.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cefoxitin cost around the world?
Cefoxitin is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Iceland publishes a max wholesale; South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 3 | 3 | ZAR███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
6 pack listings across 6 brand entries and 3 price bases, refreshed 03 Sep 2026. Ranges span every Cefoxitin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cefoxitin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Cefoxitin, across 10 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 3 | 2 | CEFOXITIN FOR INJECTION | Sourceable in Canada |
| MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | 5 | 0 | MEFOXIN INJ 1GM/VIAL ADD-VANTAG, MEFOXIN INJ 2GM/VIAL ADD-VANTAG, MEFOXIN PWS 1GM/VIAL, MEFOXIN PWS 2GM/VIAL, MEFOXIN PWS INJ 10GM/VIAL | No marketed DIN |
| PFIZER CANADA ULC | 2 | 0 | CEFOXITIN FOR INJECTION USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS ; INTRAMUSCULAR |
| Pack configuration (monograph) | 1 g (10 mL Type III glass vials), 2 g (20 mL Type III glass vials), 10 g (100 mL Type I Pharmacy Bulk Vial). |
| Storage | Store at room temperature between 15 and 30°C. Protect from light. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Cefoxitin |
|---|---|
| ATC code | J01DC01 |
| AHFS class | 08:12.07.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02128187 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2128187 |
| Brand name | CEFOXITIN FOR INJECTION |
| Generic / active ingredient | CEFOXITIN (CEFOXITIN SODIUM) : 1 G |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | J01DC01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DC |
| Current status | MARKETED |
| Status date | 22-Nov-2013 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 1-2 g every 6-8 hours (max 12 g/day). Prophylaxis: 2 g prior to surgery, then 2 g every 2-6 hours for 12-24 hours. Adjust dose in renal impairment. IV or IM administration.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to cefoxitin or other cephalosporin antibiotics. Not recommended for the treatment of meningitis.
Warnings and precautions
Potential cross-allergenicity with penicillins. Risk of anaphylaxis. Pseudomembranous colitis and severe cutaneous adverse reactions (SCAR) like SJS/TEN have been reported.
Is Cefoxitin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by TEVA CANADA LIMITED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFOXITIN FOR INJECTION | 2 G | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | 02128195 |
| CEFOXITIN FOR INJECTION | 10 G | POWDER FOR SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02240773 |
| CEFOXITIN FOR INJECTION USP | 2 G | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02291738 |
| CEFOXITIN FOR INJECTION USP | 1 G | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02291711 |
| MEFOXIN INJ 1GM/VIAL ADD-VANTAG | 1 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | 00893668 |
| MEFOXIN INJ 2GM/VIAL ADD-VANTAG | 2 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | 00893676 |
| MEFOXIN PWS 1GM/VIAL | 1 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | 00663697 |
| MEFOXIN PWS 2GM/VIAL | 2 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | 00663700 |
| MEFOXIN PWS INJ 10GM/VIAL | 10 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | 01980653 |
2 · Same class — other molecules in ATC J01DC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Cefuroxime | APO-CEFUROXIME · AURO-CEFUROXIME · CEFTIN · CEFTIN - PWR 250MG/SACHET · +23 more | 44 | 9 | Yes |
| Cefprozil | APO-CEFPROZIL · AURO-CEFPROZIL · AVA-CEFPROZIL · CEFPROZIL · +11 more | 34 | 7 | Yes |
| Cefoxitin | CEFOXITIN FOR INJECTION · CEFOXITIN FOR INJECTION USP · MEFOXIN INJ 1GM/VIAL ADD-VANTAG · MEFOXIN INJ 2GM/VIAL ADD-VANTAG · +3 more | 10 | 2 | Yes |
| Cefaclor | APO-CEFACLOR · CECLOR · CEFACLOR · CEFACLOR CAPSULES · +15 more | 41 | 0 | Not in Canada |
| Cefamandole | MANDOL ADD-VANTAGE INJ 1GM/VIAL · MANDOL INJ 1GM/AMP · MANDOL INJ 2GM/AMP | 3 | 0 | Not in Canada |
| Cefotetan | CEFOTAN INJ 2GM/VIAL · CEFOTAN INJECTION - 1G · CEFOTAN INJECTION - 2 G | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DB | Cefadroxil · Cefalexin · Cefalotin · Cefazolin | 91 | 41 |
| J01DD | Cefixime · Cefotaxime · Cefpodoxime · Ceftazidime · Ceftizoxime · +1 more | 96 | 25 |
| J01DH | Doripenem · Ertapenem · Imipenem And Cilastatin · Meropenem · Meropenem And Vaborbactam | 51 | 24 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CEFOXITIN FOR INJECTION called?
The same molecule, Cefoxitin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Cefoxitin | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.